1
|
Wunderle V, Wilhelm T, Boukeileh S, Goßen J, Margreiter MA, Sakurov R, Capellmann S, Schwoerer M, Ahmed N, Bronneberg G, Arock M, Martin C, Schubert T, Levi‐Schaffer F, Rossetti G, Tirosh B, Huber M. KIRA6 is an Effective and Versatile Mast Cell Inhibitor of IgE-mediated Activation. Eur J Immunol 2025; 55:e202451348. [PMID: 39676406 PMCID: PMC11830387 DOI: 10.1002/eji.202451348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2024] [Revised: 11/12/2024] [Accepted: 11/21/2024] [Indexed: 12/17/2024]
Abstract
Mast cell (MC)-driven allergic diseases are constantly expanding and require the development of novel pharmacological MC stabilizers. Allergen/antigen (Ag)-triggered activation via crosslinking of the high-affinity receptor for IgE (FcεRI) is fundamentally regulated by SRC family kinases, for example, LYN and FYN, exhibiting positive and negative functions. We report that KIRA6, an inhibitor for the endoplasmic reticulum stress sensor IRE1α, suppresses IgE-mediated MC activation by inhibiting both LYN and FYN. KIRA6 attenuates Ag-stimulated early signaling and effector functions such as degranulation and proinflammatory cytokine production/secretion in murine bone marrow-derived MCs. Moreover, Ag-triggered bronchoconstriction in an ex vivo model and IgE-mediated stimulation of human MCs were repressed by KIRA6. The interaction of KIRA6 with three MC-relevant tyrosine kinases, LYN, FYN, and KIT, and the potential of KIRA6 structure as a pharmacophore for the development of respective single-, dual-, or triple-specificity inhibitors, was evaluated by homology modeling and molecular dynamics simulations. We found that KIRA6 particularly strongly binds the inactive state of LYN, FYN, and KIT with comparable affinities. In conclusion, our data suggest that the chemical structure of KIRA6 as a pharmacophore can be further developed to obtain an effective MC stabilizer.
Collapse
Affiliation(s)
- Veronika Wunderle
- Institute of Biochemistry and Molecular ImmunologyMedical FacultyRWTH Aachen UniversityAachenGermany
- Department of Neurology, Faculty of Medicine and University Hospital CologneUniversity of CologneCologneGermany
| | - Thomas Wilhelm
- Institute of Biochemistry and Molecular ImmunologyMedical FacultyRWTH Aachen UniversityAachenGermany
| | - Shatha Boukeileh
- The School of PharmacyThe Hebrew University of JerusalemJerusalemIsrael
| | - Jonas Goßen
- Institute for Advanced Simulation, Jülich Supercomputing CentreForschungszentrum Jülich GmbHJülichGermany
| | - Michael A. Margreiter
- Institute for Advanced Simulation, Jülich Supercomputing CentreForschungszentrum Jülich GmbHJülichGermany
| | - Roman Sakurov
- Institute of Biochemistry and Molecular ImmunologyMedical FacultyRWTH Aachen UniversityAachenGermany
| | - Sandro Capellmann
- Institute of Biochemistry and Molecular ImmunologyMedical FacultyRWTH Aachen UniversityAachenGermany
| | - Maike Schwoerer
- Institute of Biochemistry and Molecular ImmunologyMedical FacultyRWTH Aachen UniversityAachenGermany
| | - Nabil Ahmed
- Institute of Biochemistry and Molecular ImmunologyMedical FacultyRWTH Aachen UniversityAachenGermany
| | - Gina Bronneberg
- Institute of Biochemistry and Molecular ImmunologyMedical FacultyRWTH Aachen UniversityAachenGermany
| | - Michel Arock
- Department of Hematological Biology, Pitié‐Salpêtrière Charles‐Foix HospitalAP‐HP Sorbonne UniversityParisFrance
| | - Christian Martin
- Institute of Pharmacology and Toxicology, Medical FacultyRWTH Aachen UniversityAachenGermany
| | | | | | - Giulia Rossetti
- Institute for Advanced Simulation, Jülich Supercomputing CentreForschungszentrum Jülich GmbHJülichGermany
- Jülich Supercomputing Centre (JSC)Forschungszentrum Jülich GmbHJülichGermany
- Department of NeurologyUniversity Hospital Aachen, RWTH Aachen UniversityAachenGermany
| | - Boaz Tirosh
- The School of PharmacyThe Hebrew University of JerusalemJerusalemIsrael
- Department of BiochemistryCase Western Reserve UniversityClevelandOhioUSA
| | - Michael Huber
- Institute of Biochemistry and Molecular ImmunologyMedical FacultyRWTH Aachen UniversityAachenGermany
| |
Collapse
|
2
|
Lehmann M, Krishnan R, Sucre J, Kulkarni HS, Pineda RH, Anderson C, Banovich NE, Behrsing HP, Dean CH, Haak A, Gosens R, Kaminski N, Zagorska A, Koziol-White C, Metcalf JP, Kim YH, Loebel C, Neptune E, Noel A, Raghu G, Sewald K, Sharma A, Suki B, Sperling A, Tatler A, Turner S, Rosas IO, van Ry P, Wille T, Randell SH, Pryhuber G, Rojas M, Bourke J, Königshoff M. Precision Cut Lung Slices: Emerging Tools for Preclinical and Translational Lung Research. An Official American Thoracic Society Workshop Report. Am J Respir Cell Mol Biol 2024; 72:16-31. [PMID: 39499861 PMCID: PMC11707673 DOI: 10.1165/rcmb.2024-0479st] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2024] [Indexed: 11/07/2024] Open
Abstract
The urgent need for effective treatments for acute and chronic lung diseases underscores the significance of developing innovative preclinical human research tools. The 2023 ATS Workshop on Precision Cut Lung Slices (PCLS) brought together 35 experts to discuss and address the role of human tissue-derived PCLS as a unique tool for target and drug discovery and validation in pulmonary medicine. With increasing interest and usage, along with advancements in methods and technology, there is a growing need for consensus on PCLS methodology and readouts. The current document recommends standard reporting criteria and emphasizes the requirement for careful collection and integration of clinical metadata. We further discuss current clinically relevant readouts that can be applied to PCLS and highlight recent developments and future steps for implementing novel technologies for PCLS modeling and analysis. The collection and correlation of clinical metadata and multiomic analysis will further advent the integration of this preclinical platform into patient endotyping and the development of tailored therapies for lung disease patients.
Collapse
Affiliation(s)
- Mareike Lehmann
- Philipps University Marburg, Institute for Lung Research, Marburg, Germany
- Helmholtz Center Munich, Institute for Lung Health and Immunity, Munich, Germany;
| | - Ramaswamy Krishnan
- Beth Israel Deaconess Medical Center, Emergency Medicine, Boston, United States
| | - Jennifer Sucre
- Vanderbilt University Medical Center, Pediatrics, Nashville, Tennessee, United States
| | - Hrishikesh S Kulkarni
- Washington University in Saint Louis, Division of Pulmonary and Critical Care Medicine, Saint Louis, Missouri, United States
| | - Ricardo H Pineda
- University of Pittsburgh, Division of Pulmonary, Allergy and Critical Care Medicine, Pittsburgh, Pennsylvania, United States
| | | | | | - Holger P Behrsing
- Institute for In Vitro Sciences Inc, Gaithersburg, Maryland, United States
| | - Charlotte H Dean
- Imperial College, National Heart and Lung Institute, London, United Kingdom of Great Britain and Northern Ireland
| | - Andrew Haak
- Mayo Clinic College of Medicine, Rochester, Minnesota, United States
| | - Reinoud Gosens
- University of Groningen, Molecular Pharmacology, Groningen, Netherlands
| | - Naftali Kaminski
- Yale School of Medicine , Pulmonary, Critical Care and Sleep Mediine , New Haven, Connecticut, United States
| | - Anna Zagorska
- Gilead Sciences Inc, Foster City, California, United States
| | - Cynthia Koziol-White
- Rutgers Institute for Translational Medicine and Science, Child Health Institute, Rutgers University, New Brunswick, New Jersey, United States
| | - Jordan P Metcalf
- The University of Oklahoma Health Sciences Center, Medicine, Oklahoma City, Oklahoma, United States
| | - Yong Ho Kim
- U.S. Environmental Protection Agency, Research Triangle Park, North Carolina, United States
| | | | - Enid Neptune
- Johns Hopkins, Medicine/Pulmonary and Critical Care, Baltimore, Maryland, United States
| | - Alexandra Noel
- Louisiana State University, Baton Rouge, Louisiana, United States
| | - Ganesh Raghu
- University of Washington Medical Center, Division of Pulmonary and Critical Care Medicine, Seattle, Washington, United States
| | | | - Ashish Sharma
- University of Florida, Gainesville, Florida, United States
| | - Bela Suki
- Boston University, Biomedical Engineering, Boston, Massachusetts, United States
| | - Anne Sperling
- University of Virginia School of Medicine, Charlottesville, Virginia, United States
| | - Amanda Tatler
- University of Nottingham, Respiratory Medicine , Nottingham, United Kingdom of Great Britain and Northern Ireland
| | - Scott Turner
- Pliant Therapeutics, South San Francisco, California, United States
| | - Ivan O Rosas
- Brigham and Women's Hospital, Department of Medicine, Division of Pulmonary and Critical Care Medicine, Boston, Massachusetts, United States
| | - Pam van Ry
- Brigham Young University, Chemistry and Biochemistry, Provo, Utah, United States
| | - Timo Wille
- Bundeswehr Institute of Pharmacology and Toxicology, Bundeswehr Medical Academy, Germany, Munich, Germany
| | - Scott H Randell
- University of North Carolina, Department of Cell Biology & Physiology, Chapel Hill, North Carolina, United States
| | - Gloria Pryhuber
- University of Rochester, Pediatrics, Rochester, New York, United States
| | - Mauricio Rojas
- Ohio State University, Columbus, OH, Pulmonary, Critical Care and Sleep Medicine, College of Medicine, , Columbus, Ohio, United States
| | - Jane Bourke
- Monash University, Department of Pharmacology, Biomedicine Discovery Institute, Clayton, Victoria, Australia
| | - Melanie Königshoff
- University of Pittsburgh, Medicine, Pittsburgh, Pennsylvania, United States
| |
Collapse
|
3
|
Wigenstam E, Bucht A, Thors L. Cellular responses following ex vivo lung exposure to the nerve agent VX - Potential for additional treatment targets? Chem Biol Interact 2024; 403:111225. [PMID: 39233266 DOI: 10.1016/j.cbi.2024.111225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2024] [Revised: 08/12/2024] [Accepted: 09/02/2024] [Indexed: 09/06/2024]
Abstract
Following inhalation exposure to organophosphorus nerve agents, symptoms rapidly develop and severe respiratory symptoms, such as bronchorrhea and bronchoconstriction are the leading causes of lethality. Nerve agent-induced lung injury is little investigated and the standard treatment for symptomatic relief targets the enzyme acetylcholinesterase and muscarinic acetylcholine and GABAergic receptors. In the present study, cellular responses in lung tissue during the acute (40 min) and extended phase (24 h) following severe exposure to the nerve agent VX have been investigated using an ex vivo rat precision-cut lung slice model including electrostimulation to induce a cholinergic response. Changes in protein amount, cell viability, together with, inflammatory and oxidative stress markers have been determined in both the lung tissue and incubation medium. During the acute phase, VX caused significantly increased airway contraction and decreased airway relaxation. Five micromolar of VX did not affect the sample protein levels and cell viability in lung tissue. Among seven markers of cellular responses investigated in the lung tissue, increased levels of heme oxygenase-1 and matrix metalloproteinase-9 together with decreased levels of glutathione in the incubation medium were observed in the acute phase following VX-exposure compared to electrostimulation only. No difference in cellular response was observed following VX-exposure for 24 h compared to the air control. In comparison, LPS-exposure resulted in time-dependent changes in all markers of inflammation and oxidative response. In conclusion, the present study demonstrated VX-specific patterns of oxidative responses in the lung, as well as, signs of inflammatory response and remodelling of extracellular matrix. These potential mechanisms of tissue injury should be further investigated for their potential as additional therapeutic targets during the acute phase of intoxication.
Collapse
Affiliation(s)
| | - Anders Bucht
- Swedish Defence Research Agency, CBRN Defence and Security, Umeå, Sweden
| | - Lina Thors
- Swedish Defence Research Agency, CBRN Defence and Security, Umeå, Sweden.
| |
Collapse
|
4
|
Koziol-White C, Gebski E, Cao G, Panettieri RA. Precision cut lung slices: an integrated ex vivo model for studying lung physiology, pharmacology, disease pathogenesis and drug discovery. Respir Res 2024; 25:231. [PMID: 38824592 PMCID: PMC11144351 DOI: 10.1186/s12931-024-02855-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2024] [Accepted: 05/18/2024] [Indexed: 06/03/2024] Open
Abstract
Precision Cut Lung Slices (PCLS) have emerged as a sophisticated and physiologically relevant ex vivo model for studying the intricacies of lung diseases, including fibrosis, injury, repair, and host defense mechanisms. This innovative methodology presents a unique opportunity to bridge the gap between traditional in vitro cell cultures and in vivo animal models, offering researchers a more accurate representation of the intricate microenvironment of the lung. PCLS require the precise sectioning of lung tissue to maintain its structural and functional integrity. These thin slices serve as invaluable tools for various research endeavors, particularly in the realm of airway diseases. By providing a controlled microenvironment, precision-cut lung slices empower researchers to dissect and comprehend the multifaceted interactions and responses within lung tissue, thereby advancing our understanding of pulmonary pathophysiology.
Collapse
Affiliation(s)
- Cynthia Koziol-White
- Rutgers Institute for Translational Medicine and Science, The State University of NJ, 08901, Rutgers, New Brunswick, NJ, USA.
| | - Eric Gebski
- Rutgers Institute for Translational Medicine and Science, The State University of NJ, 08901, Rutgers, New Brunswick, NJ, USA
| | - Gaoyaun Cao
- Rutgers Institute for Translational Medicine and Science, The State University of NJ, 08901, Rutgers, New Brunswick, NJ, USA
| | - Reynold A Panettieri
- Rutgers Institute for Translational Medicine and Science, The State University of NJ, 08901, Rutgers, New Brunswick, NJ, USA
| |
Collapse
|
5
|
Walker MT, Bloodworth JC, Kountz TS, McCarty SL, Green JE, Ferrie RP, Campbell JA, Averill SH, Beckman KB, Grammer LC, Eng C, Avila PC, Farber HJ, Rodriguez-Cintron W, Rodriguez-Santana JR, Serebrisky D, Thyne SM, Seibold MA, Burchard EG, Kumar R, Cook-Mills JM. 5-HTP inhibits eosinophilia via intracellular endothelial 5-HTRs; SNPs in 5-HTRs associate with asthmatic lung function. FRONTIERS IN ALLERGY 2024; 5:1385168. [PMID: 38845678 PMCID: PMC11153829 DOI: 10.3389/falgy.2024.1385168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2024] [Accepted: 05/08/2024] [Indexed: 06/09/2024] Open
Abstract
Background Previous research showed that 5-hydroxytryptophan (5HTP), a metabolic precursor of serotonin, reduces allergic lung inflammation by inhibiting eosinophil migration across endothelial monolayers. Objective It is unknown if serotonin receptors are involved in mediating this 5HTP function or if serotonin receptor (HTR) single nucleotide polymorphisms (SNPs) associate with lung function in humans. Methods Serotonin receptor subtypes were assessed by qPCR, western blot, confocal microscopy, pharmacological inhibitors and siRNA knockdown. HTR SNPs were assessed in two cohorts. Results Pharmacological inhibition or siRNA knockdown of the serotonin receptors HTR1A or HTR1B in endothelial cells abrogated the inhibitory effects of 5HTP on eosinophil transendothelial migration. In contrast, eosinophil transendothelial migration was not inhibited by siRNA knockdown of HTR1A or HTR1B in eosinophils. Surprisingly, these HTRs were intracellular in endothelial cells and an extracellular supplementation with serotonin did not inhibit eosinophil transendothelial migration. This is consistent with the inability of serotonin to cross membranes, the lack of selective serotonin reuptake receptors on endothelial cells, and the studies showing minimal impact of selective serotonin reuptake inhibitors on asthma. To extend our HTR studies to humans with asthma, we examined the CHIRAH and GALA cohorts for HTR SNPs that affect HTR function or are associated with behavior disorders. A polygenic index of SNPs in HTRs was associated with lower lung function in asthmatics. Conclusions Serotonin receptors mediate 5HTP inhibition of transendothelial migration and HTR SNPs associate with lower lung function. These results may serve to aid in design of novel interventions for allergic inflammation.
Collapse
Affiliation(s)
- Matthew T. Walker
- Allergy-Immunology Division, Northwestern University Feinberg School of Medicine, Chicago, IL, United States
| | - Jeffrey C. Bloodworth
- Herman B Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, United States
- Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, United States
| | - Timothy S. Kountz
- Allergy-Immunology Division, Northwestern University Feinberg School of Medicine, Chicago, IL, United States
| | - Samantha L. McCarty
- Herman B Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, United States
| | - Jeremy E. Green
- Allergy-Immunology Division, Northwestern University Feinberg School of Medicine, Chicago, IL, United States
| | - Ryan P. Ferrie
- Allergy-Immunology Division, Northwestern University Feinberg School of Medicine, Chicago, IL, United States
| | - Jackson A. Campbell
- Allergy-Immunology Division, Northwestern University Feinberg School of Medicine, Chicago, IL, United States
| | - Samantha H. Averill
- Herman B Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, United States
| | | | - Leslie C. Grammer
- Allergy-Immunology Division, Northwestern University Feinberg School of Medicine, Chicago, IL, United States
| | - Celeste Eng
- Department of Medicine, University of California, San Francisco, San Francisco, CA, United States
| | - Pedro C. Avila
- Allergy-Immunology Division, Northwestern University Feinberg School of Medicine, Chicago, IL, United States
| | - Harold J. Farber
- Department of Pediatrics, Section of Pulmonology, Baylor College of Medicine, Texas Children’s Hospital, Houston, TX, United States
| | | | | | - Denise Serebrisky
- Pediatric Pulmonary Division, Jacobi Medical Center, Bronx, NY, United States
| | - Shannon M. Thyne
- Department of Pediatrics, University of California, San Francisco, San Francisco, CA, United States
| | - Max A. Seibold
- Center for Genes, Environment, and Health and the Department of Pediatrics, National Jewish Health, Denver, CO, United States
- Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado, Denver, CO, United States
| | - Esteban G. Burchard
- Department of Medicine, University of California, San Francisco, San Francisco, CA, United States
| | - Rajesh Kumar
- Allergy-Immunology Division, Northwestern University Feinberg School of Medicine, Chicago, IL, United States
- Division of Allergy and Clinical Immunology, Ann and Robert H Lurie Children’s Hospital of Chicago, Chicago, IL, United States
| | - Joan M. Cook-Mills
- Allergy-Immunology Division, Northwestern University Feinberg School of Medicine, Chicago, IL, United States
- Herman B Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, United States
- Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, United States
| |
Collapse
|
6
|
Calzetta L, Page C, Matera MG, Cazzola M, Rogliani P. Use of human airway smooth muscle in vitro and ex vivo to investigate drugs for the treatment of chronic obstructive respiratory disorders. Br J Pharmacol 2024; 181:610-639. [PMID: 37859567 DOI: 10.1111/bph.16272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2023] [Revised: 10/11/2023] [Accepted: 10/12/2023] [Indexed: 10/21/2023] Open
Abstract
Isolated airway smooth muscle has been extensively investigated since 1840 to understand the pharmacology of airway diseases. There has often been poor predictability from murine experiments to drugs evaluated in patients with asthma or chronic obstructive pulmonary disease (COPD). However, the use of isolated human airways represents a sensible strategy to optimise the development of innovative molecules for the treatment of respiratory diseases. This review aims to provide updated evidence on the current uses of isolated human airways in validated in vitro methods to investigate drugs in development for the treatment of chronic obstructive respiratory disorders. This review also provides historical notes on the pioneering pharmacological research on isolated human airway tissues, the key differences between human and animal airways, as well as the pivotal differences between human medium bronchi and small airways. Experiments carried out with isolated human bronchial tissues in vitro and ex vivo replicate many of the main anatomical, pathophysiological, mechanical and immunological characteristics of patients with asthma or COPD. In vitro models of asthma and COPD using isolated human airways can provide information that is directly translatable into humans with obstructive lung diseases. Regardless of the technique used to investigate drugs for the treatment of chronic obstructive respiratory disorders (i.e., isolated organ bath systems, videomicroscopy and wire myography), the most limiting factors to produce high-quality and repeatable data remain closely tied to the manual skills of the researcher conducting experiments and the availability of suitable tissue.
Collapse
Affiliation(s)
- Luigino Calzetta
- Department of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy
| | - Clive Page
- Pulmonary Pharmacology Unit, Institute of Pharmaceutical Science, King's College London, London, UK
| | - Maria Gabriella Matera
- Unit of Pharmacology, Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Mario Cazzola
- Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy
| | - Paola Rogliani
- Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy
| |
Collapse
|
7
|
Wigenstam E, Artursson E, Bucht A, Thors L. Supplemental treatment to atropine improves the efficacy to reverse nerve agent induced bronchoconstriction. Chem Biol Interact 2022; 364:110061. [PMID: 35872047 DOI: 10.1016/j.cbi.2022.110061] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Revised: 06/23/2022] [Accepted: 07/13/2022] [Indexed: 12/29/2022]
Abstract
Exposure to highly toxic organophosphorus compounds causes inhibition of the enzyme acetylcholinesterase resulting in a cholinergic toxidrome and innervation of receptors in the neuromuscular junction may cause life-threatening respiratory effects. The involvement of several receptor systems was therefore examined for their impact on bronchoconstriction using an ex vivo rat precision-cut lung slice (PCLS) model. The ability to recover airways with therapeutics following nerve agent exposure was determined by quantitative analyses of muscle contraction. PCLS exposed to nicotine resulted in a dose-dependent bronchoconstriction. The neuromuscular nicotinic antagonist tubocurarine counteracted the nicotine-induced bronchoconstriction but not the ganglion blocker mecamylamine or the common muscarinic antagonist atropine. Correspondingly, atropine demonstrated a significant airway relaxation following ACh-exposure while tubocurarine did not. Atropine, the M3 muscarinic receptor antagonist 4-DAMP, tubocurarine, the β2-adrenergic receptor agonist formoterol, the Na+-channel blocker tetrodotoxin and the KATP-channel opener cromakalim all significantly decreased airway contractions induced by electric field stimulation. Following VX-exposure, treatment with atropine and the Ca2+-channel blocker magnesium sulfate resulted in significant airway relaxation. Formoterol, cromakalim and magnesium sulfate administered in combinations with atropine demonstrated an additive effect. In conclusion, the present study demonstrated improved airway function following nerve agent exposure by adjunct treatment to the standard therapy of atropine.
Collapse
Affiliation(s)
| | - Elisabet Artursson
- Swedish Defence Research Agency, CBRN Defence and Security, Umeå, Sweden
| | - Anders Bucht
- Swedish Defence Research Agency, CBRN Defence and Security, Umeå, Sweden
| | - Lina Thors
- Swedish Defence Research Agency, CBRN Defence and Security, Umeå, Sweden.
| |
Collapse
|
8
|
Wigenstam E, Forsberg E, Bucht A, Thors L. Efficacy of atropine and scopolamine on airway contractions following exposure to the nerve agent VX. Toxicol Appl Pharmacol 2021; 419:115512. [PMID: 33785355 DOI: 10.1016/j.taap.2021.115512] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2021] [Revised: 03/10/2021] [Accepted: 03/25/2021] [Indexed: 11/25/2022]
Abstract
Nerve agents are highly toxic organophosphorus compounds that inhibit acetylcholinesterase resulting in rapid accumulation of the neurotransmitter acetylcholine (ACh) causing a cholinergic syndrome including respiratory failure. In the present study, respiratory responses and antimuscarinic treatment efficacy was evaluated ex vivo using rat precision-cut lung slices (PCLS) exposed to the nerve agent VX. The respiratory effects were evaluated either by adding exogenous ACh directly to the culture medium or by applying electric-field stimulation (EFS) to the PCLS to achieve a release of endogenous ACh from neurons in the lung tissue. The airway contraction induced by both methods was enhanced by VX and resulted in lingering airway recovery, in particular when airways were exposed to a high VX-dose. Both contractions induced by EFS and exogenously added ACh were significantly reduced by administration of the antimuscarinic drugs atropine or scopolamine. Two additions of atropine or scopolamine after maximal ACh-induced airway response was demonstrated effective to reverse the contraction. By adding consecutive doubled doses of antimuscarinics, high efficiency to reduce the cholinergic airway response was observed. However, the airways were not completely recovered by atropine or scopolamine, indicating that non-muscarinic mechanisms were involved in the smooth muscle contractions. In conclusion, it was demonstrated that antimuscarinic treatment reversed airway contraction induced by VX but supplemental pharmacological interventions are needed to fully recover the airways. Further studies should therefore clarify the mechanisms of physiological responses in lung tissue following nerve agent exposures to improve the medical management of poisoned individuals.
Collapse
Affiliation(s)
- E Wigenstam
- Swedish Defence Research Agency, CBRN Defence and Security, Umeå, Sweden
| | - E Forsberg
- Swedish Defence Research Agency, CBRN Defence and Security, Umeå, Sweden
| | - A Bucht
- Swedish Defence Research Agency, CBRN Defence and Security, Umeå, Sweden
| | - L Thors
- Swedish Defence Research Agency, CBRN Defence and Security, Umeå, Sweden.
| |
Collapse
|
9
|
Bigaeva E, Gore E, Simon E, Zwick M, Oldenburger A, de Jong KP, Hofker HS, Schlepütz M, Nicklin P, Boersema M, Rippmann JF, Olinga P. Transcriptomic characterization of culture-associated changes in murine and human precision-cut tissue slices. Arch Toxicol 2019; 93:3549-3583. [PMID: 31754732 DOI: 10.1007/s00204-019-02611-6] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2019] [Accepted: 11/05/2019] [Indexed: 12/14/2022]
Abstract
Our knowledge of complex pathological mechanisms underlying organ fibrosis is predominantly derived from animal studies. However, relevance of animal models for human disease is limited; therefore, an ex vivo model of human precision-cut tissue slices (PCTS) might become an indispensable tool in fibrosis research and drug development by bridging the animal-human translational gap. This study, presented as two parts, provides comprehensive characterization of the dynamic transcriptional changes in PCTS during culture by RNA sequencing. Part I investigates the differences in culture-induced responses in murine and human PCTS derived from healthy liver, kidney and gut. Part II delineates the molecular processes in cultured human PCTS generated from diseased liver, kidney and ileum. We demonstrated that culture was associated with extensive transcriptional changes and impacted PCTS in a universal way across the organs and two species by triggering an inflammatory response and fibrosis-related extracellular matrix (ECM) remodelling. All PCTS shared mRNA upregulation of IL-11 and ECM-degrading enzymes MMP3 and MMP10. Slice preparation and culturing activated numerous pathways across all PCTS, especially those involved in inflammation (IL-6, IL-8 and HMGB1 signalling) and tissue remodelling (osteoarthritis pathway and integrin signalling). Despite the converging effects of culture, PCTS display species-, organ- and pathology-specific differences in the regulation of genes and canonical pathways. The underlying pathology in human diseased PCTS endures and influences biological processes like cytokine release. Our study reinforces the use of PCTS as an ex vivo fibrosis model and supports future studies towards its validation as a preclinical tool for drug development.
Collapse
Affiliation(s)
- Emilia Bigaeva
- Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, Groningen, 9713AV, The Netherlands
| | - Emilia Gore
- Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, Groningen, 9713AV, The Netherlands
| | - Eric Simon
- Computational Biology, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397, Biberach an der Riss, Germany
| | - Matthias Zwick
- Computational Biology, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397, Biberach an der Riss, Germany
| | - Anouk Oldenburger
- Cardiometabolic Disease Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397, Biberach an der Riss, Germany
| | - Koert P de Jong
- Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands
| | - Hendrik S Hofker
- Department of Surgery, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands
| | - Marco Schlepütz
- Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397, Biberach an der Riss, Germany
| | - Paul Nicklin
- Research Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397, Biberach an der Riss, Germany
| | - Miriam Boersema
- Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, Groningen, 9713AV, The Netherlands
| | - Jörg F Rippmann
- Cardiometabolic Disease Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397, Biberach an der Riss, Germany
| | - Peter Olinga
- Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, Groningen, 9713AV, The Netherlands.
| |
Collapse
|
10
|
Wu X, van Dijk EM, Bos IST, Kistemaker LEM, Gosens R. Mouse Lung Tissue Slice Culture. Methods Mol Biol 2019; 1940:297-311. [PMID: 30788834 DOI: 10.1007/978-1-4939-9086-3_21] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
Precision-cut lung slices (PCLS) represent an ex vivo model widely used in visualizing interactions between lung structure and function. The major advantage of this technique is that the presence, differentiation state, and localization of the more than 40 cell types that make up the lung are in accordance with the physiological situation found in lung tissue, including the right localization and patterning of extracellular matrix elements. Here we describe the methodology involved in preparing and culturing PCLS followed by detailed practical information about their possible applications.
Collapse
Affiliation(s)
- Xinhui Wu
- Faculty of Science and Engineering, Department of Molecular Pharmacology, University of Groningen, Groningen, The Netherlands.,Groningen Research Institute for Asthma and COPD, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Eline M van Dijk
- Faculty of Science and Engineering, Department of Molecular Pharmacology, University of Groningen, Groningen, The Netherlands.,Groningen Research Institute for Asthma and COPD, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - I Sophie T Bos
- Faculty of Science and Engineering, Department of Molecular Pharmacology, University of Groningen, Groningen, The Netherlands.,Groningen Research Institute for Asthma and COPD, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Loes E M Kistemaker
- Faculty of Science and Engineering, Department of Molecular Pharmacology, University of Groningen, Groningen, The Netherlands.,Groningen Research Institute for Asthma and COPD, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Reinoud Gosens
- Faculty of Science and Engineering, Department of Molecular Pharmacology, University of Groningen, Groningen, The Netherlands. .,Groningen Research Institute for Asthma and COPD, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
| |
Collapse
|
11
|
Calzetta L, Rogliani P, Page C, Rinaldi B, Cazzola M, Matera MG. Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. Pulm Pharmacol Ther 2019; 56:39-50. [DOI: 10.1016/j.pupt.2019.03.004] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2019] [Revised: 03/08/2019] [Accepted: 03/08/2019] [Indexed: 12/20/2022]
|
12
|
Kennedy JL, Kurten RC, McCullough S, Panettieri RA, Koziol-White C, Jones SM, Caid K, Gill PS, Roberts D, Jaeschke H, McGill MR, James L. Acetaminophen is both bronchodilatory and bronchoprotective in human precision cut lung slice airways. Xenobiotica 2019; 49:1106-1115. [PMID: 30328361 DOI: 10.1080/00498254.2018.1536814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
Epidemiologic studies have demonstrated an association between acetaminophen (APAP) use and the development of asthma symptoms. However, few studies have examined relationships between APAP-induced signaling pathways associated with the development of asthma symptoms. We tested the hypothesis that acute APAP exposure causes airway hyper-responsiveness (AHR) in human airways. Precision cut lung slice (PCLS) airways from humans and mice were used to determine the effects of APAP on airway bronchoconstriction and bronchodilation and to assess APAP metabolism in lungs. APAP did not promote AHR in normal or asthmatic human airways ex vivo. Rather, high concentrations mildly bronchodilated airways pre-constricted with carbachol (CCh), histamine (His), or immunoglobulin E (IgE) cross-linking. Further, the addition of APAP prior to bronchoconstrictors protected the airways from constriction. Similarly, in vivo treatment of mice with APAP (200 mg/kg IP) resulted in reduced bronchoconstrictor responses in PCLS airways ex vivo. Finally, in both mouse and human PCLS airways, exposure to APAP generated only low amounts of APAP-protein adducts, indicating minimal drug metabolic activity in the tissues. These findings indicate that acute exposure to APAP does not initiate AHR, that high-dose APAP is protective against bronchoconstriction, and that APAP is a mild bronchodilator.
Collapse
Affiliation(s)
- Joshua L Kennedy
- a Division of Allergy and Immunology, Department of Pediatrics , University of Arkansas for Medical Sciences , Little Rock , AR , USA.,b Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine , University of Arkansas for Medical Sciences , Little Rock , AR , USA.,c Arkansas Children's Hospital Research Institute , Little Rock , AR , USA
| | - Richard C Kurten
- a Division of Allergy and Immunology, Department of Pediatrics , University of Arkansas for Medical Sciences , Little Rock , AR , USA.,c Arkansas Children's Hospital Research Institute , Little Rock , AR , USA.,d Department of Physiology and Biophysics , University of Arkansas for Medical Sciences , Little Rock , AR , USA
| | - Sandra McCullough
- e Division of Clinical Pharmacology and Toxicology, Department of Pediatrics , University of Arkansas for Medical Sciences , Little Rock , AR , USA
| | - Reynold A Panettieri
- f Department of Medicine , Rutgers, the State University of New Jersey , New Brunswick , NJ , USA
| | - Cynthia Koziol-White
- f Department of Medicine , Rutgers, the State University of New Jersey , New Brunswick , NJ , USA
| | - Stacie M Jones
- a Division of Allergy and Immunology, Department of Pediatrics , University of Arkansas for Medical Sciences , Little Rock , AR , USA.,c Arkansas Children's Hospital Research Institute , Little Rock , AR , USA.,d Department of Physiology and Biophysics , University of Arkansas for Medical Sciences , Little Rock , AR , USA
| | - Katherine Caid
- g Department of Pediatrics , University of Arkansas for Medical Sciences , Little Rock , AR , USA
| | - Pritmohinder S Gill
- c Arkansas Children's Hospital Research Institute , Little Rock , AR , USA.,g Department of Pediatrics , University of Arkansas for Medical Sciences , Little Rock , AR , USA
| | - Dean Roberts
- e Division of Clinical Pharmacology and Toxicology, Department of Pediatrics , University of Arkansas for Medical Sciences , Little Rock , AR , USA
| | - Hartmut Jaeschke
- h Department of Pharmacology, Toxicology, and Therapeutics , University of Kansas Medical Center , Kansas City , KS , USA
| | - Mitchell R McGill
- i Department of Environmental and Occupational Health, Fay W. Boozman College of Public Health , University of Arkansas for Medical Sciences , Little Rock , AR , USA
| | - Laura James
- e Division of Clinical Pharmacology and Toxicology, Department of Pediatrics , University of Arkansas for Medical Sciences , Little Rock , AR , USA
| |
Collapse
|
13
|
Human lung tissue provides highly relevant data about efficacy of new anti-asthmatic drugs. PLoS One 2018; 13:e0207767. [PMID: 30500834 PMCID: PMC6267969 DOI: 10.1371/journal.pone.0207767] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2018] [Accepted: 11/06/2018] [Indexed: 12/11/2022] Open
Abstract
Subgroups of patients with severe asthma are insensitive to inhaled corticosteroids and require novel therapies on top of standard medical care. IL-13 is considered one of the key cytokines in the asthma pathogenesis, however, the effect of IL-13 was mostly studied in rodents. This study aimed to assess IL-13 effect in human lung tissue for the development of targeted therapy approaches such as inhibition of soluble IL-13 or its receptor IL-4Rα subunit. Precision-cut lung slices (PCLS) were prepared from lungs of rodents, non-human primates (NHP) and humans. Direct effect of IL-13 on human lung tissue was observed on inflammation, induction of mucin5AC, and airway constriction induced by methacholine and visualized by videomicroscopy. Anti-inflammatory treatment was evaluated by co-incubation of IL-13 with increasing concentrations of IL-13/IL-13 receptor inhibitors. IL-13 induced a two-fold increase in mucin5AC secretion in human bronchial tissue. Additionally, IL-13 induced release of proinflammatory cytokines eotaxin-3 and TARC in human PCLS. Anti-inflammatory treatment with four different inhibitors acting either on the IL-13 ligand itself (anti-IL-13 antibody, similar to Lebrikizumab) or the IL-4Rα chain of the IL-13/IL-4 receptor complex (anti-IL-4Rα #1, similar to AMG 317, and #2, similar to REGN668) and #3 PRS-060 (a novel anticalin directed against this receptor) could significantly attenuate IL-13 induced inflammation. Contrary to this, IL-13 did not induce airway hyperresponsiveness (AHR) in human and NHP PCLS, although it was effective in rodent PCLS. Overall, this study demonstrates that IL-13 stimulation induces production of mucus and biomarkers of allergic inflammation in human lung tissue ex-vivo but no airway hyperresponsiveness. The results of this study show a more distinct efficacy than known from animals models and a clear discrepancy in AHR induction. Moreover, it allows a translational approach in inhibitor profiling in human lung tissue.
Collapse
|
14
|
Calzetta L, Matera MG, Facciolo F, Cazzola M, Rogliani P. Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways. Respir Res 2018; 19:65. [PMID: 29650006 PMCID: PMC5897944 DOI: 10.1186/s12931-018-0770-7] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2018] [Accepted: 04/02/2018] [Indexed: 12/15/2022] Open
Abstract
Background Corticosteroids increase the expression of β2-adrenoceptors (β2-ARs) and protect them against down-regulation. Conversely, β2-AR agonists improve the anti-inflammatory action of corticosteroids. Nevertheless, it is still uncertain whether adding a long-acting β2-AR agonist (LABA) to an inhaled corticosteroid (ICS) results in an additive effect, or there is true synergy. Therefore, the aim of this study was to pharmacologically characterize the interaction between the ICS beclomethasone diproprionate (BDP) and the LABA formoterol fumarate (FF) in a validated human ex vivo model of bronchial asthma. Methods Human medium and small airways were stimulated by histamine and treated with different concentrations of BDP and FF, administered alone and in combination at concentration-ratio reproducing ex vivo that of the currently available fixed-dose combination (FDC; BDP/FF 100:6 combination-ratio). Experiments were performed in non-sensitized (NS) and passively sensitized (PS) airways. The pharmacological interaction was assessed by using Bliss Independence and Unified Theory equations. Results BDP/FF synergistically increased the overall bronchorelaxation in NS and PS airways (+ 15.15% ± 4.02%; P < 0.05 vs. additive effect). At low-to-medium concentrations the synergistic interaction was greater in PS than in NS bronchioles (+ 16.68% ± 3.02% and + 7.27% ± 3.05%, respectively). In PS small airways a very strong synergistic interaction (Combination Index: 0.08; + 20.04% ± 2.18% vs. additive effect) was detected for the total concentrations of BDP/FF combination corresponding to 10.6 ng/ml. Conclusion BDP/FF combination synergistically relaxed human bronchi; the extent of such an interaction was very strong at low-to-medium concentrations in PS small airways. Trial registration Not applicable. Electronic supplementary material The online version of this article (10.1186/s12931-018-0770-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Luigino Calzetta
- Unit of Respiratory Medicine, Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy
| | - Maria Gabriella Matera
- Unit of Pharmacology, Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy
| | - Francesco Facciolo
- Thoracic Surgery Unit, "Regina Elena" National Cancer Institute, Rome, Italy
| | - Mario Cazzola
- Unit of Respiratory Medicine, Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy
| | - Paola Rogliani
- Unit of Respiratory Medicine, Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.
| |
Collapse
|
15
|
Kaya-Yasar Y, Karaman Y, Bozkurt TE, Onder SC, Sahin-Erdemli I. Effects of intranasal treatment with slow (GYY4137) and rapid (NaHS) donors of hydrogen sulfide in lipopolysaccharide-induced airway inflammation in mice. Pulm Pharmacol Ther 2017. [DOI: 10.1016/j.pupt.2017.06.006] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
16
|
Lilburn DML, Tatler AL, Six JS, Lesbats C, Habgood A, Porte J, Hughes-Riley T, Shaw DE, Jenkins G, Meersmann T. Investigating lung responses with functional hyperpolarized xenon-129 MRI in an ex vivo rat model of asthma. Magn Reson Med 2016; 76:1224-35. [PMID: 26507239 PMCID: PMC5026173 DOI: 10.1002/mrm.26003] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2015] [Revised: 08/26/2015] [Accepted: 09/08/2015] [Indexed: 01/08/2023]
Abstract
PURPOSE Asthma is a disease of increasing worldwide importance that calls for new investigative methods. Ex vivo lung tissue is being increasingly used to study functional respiratory parameters independent of confounding systemic considerations but also to reduce animal numbers and associated research costs. In this work, a straightforward laboratory method is advanced to probe dynamic changes in gas inhalation patterns by using an ex vivo small animal ovalbumin (OVA) model of human asthma. METHODS Hyperpolarized (hp) (129) Xe was actively inhaled by the excised lungs exposed to a constant pressure differential that mimicked negative pleural cavity pressure. The method enabled hp (129) Xe MRI of airway responsiveness to intravenous methacholine (MCh) and airway challenge reversal through salbutamol. RESULTS Significant differences were demonstrated between control and OVA challenged animals on global lung hp (129) Xe gas inhalation with P < 0.05 at MCh dosages above 460 μg. Spatial mapping of the regional hp gas distribution revealed an approximately three-fold increase in heterogeneity for the asthma model organs. CONCLUSION The experimental results from this proof of concept work suggest that the ex vivo hp noble gas imaging arrangement and the applied image analysis methodology may be useful as an adjunct to current diagnostic techniques. Magn Reson Med 76:1224-1235, 2016. © 2015 The Authors. Magnetic Resonance in Medicine published by Wiley Periodicals, Inc. on behalf of International Society for Magnetic Resonance in Medicine. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Collapse
Affiliation(s)
- David M L Lilburn
- Sir Peter Mansfield Imaging Centre, School of Medicine, University of Nottingham, Nottingham, United Kingdom
| | - Amanda L Tatler
- Division of Respiratory Medicine, Nottingham University Hospitals, City Campus, University of Nottingham, Nottingham, United Kingdom
| | - Joseph S Six
- Sir Peter Mansfield Imaging Centre, School of Medicine, University of Nottingham, Nottingham, United Kingdom
| | - Clémentine Lesbats
- Sir Peter Mansfield Imaging Centre, School of Medicine, University of Nottingham, Nottingham, United Kingdom
| | - Anthony Habgood
- Division of Respiratory Medicine, Nottingham University Hospitals, City Campus, University of Nottingham, Nottingham, United Kingdom
| | - Joanne Porte
- Division of Respiratory Medicine, Nottingham University Hospitals, City Campus, University of Nottingham, Nottingham, United Kingdom
| | - Theodore Hughes-Riley
- Sir Peter Mansfield Imaging Centre, School of Medicine, University of Nottingham, Nottingham, United Kingdom
| | - Dominick E Shaw
- Division of Respiratory Medicine, Nottingham University Hospitals, City Campus, University of Nottingham, Nottingham, United Kingdom
| | - Gisli Jenkins
- Division of Respiratory Medicine, Nottingham University Hospitals, City Campus, University of Nottingham, Nottingham, United Kingdom
| | - Thomas Meersmann
- Sir Peter Mansfield Imaging Centre, School of Medicine, University of Nottingham, Nottingham, United Kingdom.
| |
Collapse
|
17
|
Lamb DJ, Wollin SL, Schnapp A, Bischoff D, Erb KJ, Bouyssou T, Guilliard B, Strasser C, Wex E, Blum S, Thaler E, Nickel H, Radmacher O, Haas H, Swantek JL, Souza D, Canfield M, White D, Panzenbeck M, Kashem MA, Sanville-Ross M, Kono T, Sewald K, Braun A, Obernolte H, Danov O, Schaenzle G, Rast G, Maier GM, Hoffmann M. BI 1002494, a Novel Potent and Selective Oral Spleen Tyrosine Kinase Inhibitor, Displays Differential Potency in Human Basophils and B Cells. J Pharmacol Exp Ther 2016; 357:554-61. [PMID: 27048659 DOI: 10.1124/jpet.116.233155] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2016] [Accepted: 03/31/2016] [Indexed: 03/08/2025] Open
Abstract
BI 1002494 [(R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6]napthyridin-5-yloxy]-ethyl}pyrrolidin-2-one] is a novel, potent, and selective spleen tyrosine kinase (SYK) inhibitor with sustained plasma exposure after oral administration in rats, which qualifies this molecule as a good in vitro and in vivo tool compound. BI 1002494 exhibits higher potency in inhibiting high-affinity IgE receptor-mediated mast cell and basophil degranulation (IC50 = 115 nM) compared with B-cell receptor-mediated activation of B cells (IC50 = 810 nM). This may be explained by lower kinase potency when the physiologic ligand B-cell linker was used, suggesting that SYK inhibitors may exhibit differential potency depending on the cell type and the respective signal transduction ligand. A 3-fold decrease in potency was observed in rat basophils (IC50 = 323 nM) compared with human basophils, but a similar species potency shift was not observed in B cells. The lower potency in rat basophils was confirmed in both ex vivo inhibition of bronchoconstriction in precision-cut rat lung slices and in reversal of anaphylaxis-driven airway resistance in rats. The different cellular potencies translated into different in vivo efficacy; full efficacy in a rat ovalbumin model (that contains an element of mast cell dependence) was achieved with a trough plasma concentration of 340 nM, whereas full efficacy in a rat collagen-induced arthritis model (that contains an element of B-cell dependence) was achieved with a trough plasma concentration of 1400 nM. Taken together, these data provide a platform from which different estimates of human efficacious exposures can be made according to the relevant cell type for the indication intended to be treated.
Collapse
Affiliation(s)
- David J Lamb
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Stefan Lutz Wollin
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Andreas Schnapp
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Daniel Bischoff
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Klaus J Erb
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Thierry Bouyssou
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Bernd Guilliard
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Christine Strasser
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Eva Wex
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Sylvia Blum
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Eva Thaler
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Helga Nickel
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Oliver Radmacher
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Hannah Haas
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Jennifer L Swantek
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Don Souza
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Melissa Canfield
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Della White
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Mark Panzenbeck
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Mohammed A Kashem
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Mary Sanville-Ross
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Takeshi Kono
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Katherina Sewald
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Armin Braun
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Helena Obernolte
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Olga Danov
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Gerhard Schaenzle
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Georg Rast
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Gerd-Michael Maier
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| | - Matthias Hoffmann
- Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
| |
Collapse
|
18
|
Interaction between corticosteroids and muscarinic antagonists in human airways. Pulm Pharmacol Ther 2015; 36:1-9. [PMID: 26656790 DOI: 10.1016/j.pupt.2015.11.004] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/18/2015] [Revised: 11/05/2015] [Accepted: 11/25/2015] [Indexed: 12/30/2022]
Abstract
BACKGROUND To date there is emerging clinical evidence to add long-acting anti-muscarinic agents (LAMAs) with inhaled corticosteroid (ICSs) in asthma, but the pharmacological rationale that supports the use of such a combination has not yet been explained. The aim of this study was to pharmacologically investigate the interaction between the ICS beclomethasone and the LAMA glycopyrronium on the human airway smooth muscle (ASM) tone. METHODS We investigated the rapid non-genomic bronchorelaxant effect of beclomethasone and glycopyrronium, administered alone and in combination, in human isolated bronchi and bronchioles. Experiments were carried out also in passively sensitized airways and the pharmacological analysis of drug interaction was performed by Bliss Independence method. RESULTS The acute administration of beclomethasone and glycopyrronium induced a significant relaxation of passively sensitized ASM pre-contracted with histamine, by causing submaximal/maximal inhibition of the contractile tone in both medium bronchi and bronchioles. Beclomethasone was characterized by a rapid non-genomic and epithelium independent bronchorelaxant effect. In passively sensitized airways, this effect seemed to be dependent by the activation of a Gsα--cyclic adenosine monophosphate (cAMP)--protein kinase A cascade. While no synergistic interaction was detected in non-sensitized bronchi, the beclomethasone/glycopyrronium combination synergistically enhanced the relaxation of passively sensitized medium and small bronchi. The synergistic interaction between beclomethasone and glycopyrronium was associated with an increase of cAMP concentrations. CONCLUSIONS Our study provides for the first time the pharmacological rationale for combining low doses of an ICS plus a LAMA.
Collapse
|
19
|
Calzetta L, Cazzola M, Page CP, Rogliani P, Facciolo F, Matera MG. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulm Pharmacol Ther 2015; 32:15-23. [PMID: 25899618 DOI: 10.1016/j.pupt.2015.03.007] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/12/2014] [Revised: 03/02/2015] [Accepted: 03/03/2015] [Indexed: 11/19/2022]
Abstract
BACKGROUND The dual PDE3/4 inhibitor RPL 554 causes bronchodilation in patients with asthma or COPD and synergistically interacts with muscarinic receptor antagonists in relaxing human isolated bronchi in acute experimental settings. In the present study we investigated the long-lasting interaction between RPL554 and glycopyrronium by testing these drugs for their ability to relax both medium and small human isolated bronchi. METHODS The relaxant effect and duration of action of RPL554 and glycopyrronium, alone, or in combination, were studied on the contractile tone induced by electrical field stimulation (EFS) or carbachol in medium and small human isolated bronchi. Relaxation was expressed as percentage of maximal response and synergy analyzed by Bliss Independence theory. RESULTS Low concentrations of RPL554 and glycopyrronium induced maximal relaxation of medium bronchi at 160 ± 20 min and 50 ± 10 min, respectively, an effect detectable for at least 4 h. Maximal synergy was observed at ≃ 2 hrs (-71.4 ± 5.1%), and the combination extended the relaxation to at least 6 hrs, when the contractile tone was -41.2 ± 8.5% of the control responses. The combination induced the greatest effectiveness for EFS at 3 Hz and low-to-middle concentrations also produced significant synergism on small airways (21.1 ± 4.0%,P < 0.05), compared with the additive response. The combination induced lumen area enhancement of 69.1 ± 2.4% (P < 0.05), compared with the additive response (51.0 ± 5.4%). CONCLUSIONS RPL554 and glycopyrronium demonstrated a synergistic interaction in relaxing both human medium and small isolated bronchi, in terms of peak relaxation and an extended duration of action, suggesting that this combination may have a beneficial role in the treatment of asthma or COPD.
Collapse
Affiliation(s)
- Luigino Calzetta
- Department of Systems Medicine, University of Rome 'Tor Vergata', Rome, Italy.
| | - Mario Cazzola
- Department of Systems Medicine, University of Rome 'Tor Vergata', Rome, Italy
| | - Clive P Page
- Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King's College London, London, UK
| | - Paola Rogliani
- Department of Systems Medicine, University of Rome 'Tor Vergata', Rome, Italy
| | | | | |
Collapse
|
20
|
Cazzola M, Calzetta L, Page CP, Rogliani P, Facciolo F, Gavaldà A, Matera MG. Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. Eur J Pharmacol 2014; 745:135-43. [DOI: 10.1016/j.ejphar.2014.10.025] [Citation(s) in RCA: 73] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2014] [Revised: 10/13/2014] [Accepted: 10/15/2014] [Indexed: 02/04/2023]
|
21
|
Lambermont VA, Schlepütz M, Dassow C, König P, Zimmermann LJ, Uhlig S, Kramer BW, Martin C. Comparison of airway responses in sheep of different age in precision-cut lung slices (PCLS). PLoS One 2014; 9:e97610. [PMID: 25229890 PMCID: PMC4167544 DOI: 10.1371/journal.pone.0097610] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2013] [Accepted: 04/22/2014] [Indexed: 12/16/2022] Open
Abstract
Background Animal models should display important characteristics of the human disease. Sheep have been considered particularly useful to study allergic airway responses to common natural antigens causing human asthma. A rationale of this study was to establish a model of ovine precision-cut lung slices (PCLS) for the in vitro measurement of airway responses in newborn and adult animals. We hypothesized that differences in airway reactivity in sheep are present at different ages. Methods Lambs were delivered spontaneously at term (147d) and adult sheep lived till 18 months. Viability of PCLS was confirmed by the MTT-test. To study airway provocations cumulative concentration-response curves were performed with different allergic response mediators and biogenic amines. In addition, electric field stimulation, passive sensitization with house dust mite (HDM) and mast cells staining were evaluated. Results PCLS from sheep were viable for at least three days. PCLS of newborn and adult sheep responded equally strong to methacholine and endothelin-1. The responses to serotonin, leukotriene D4 and U46619 differed with age. No airway contraction was evoked by histamine, except after cimetidine pretreatment. In response to EFS, airways in PCLS from adult and newborn sheep strongly contracted and these contractions were atropine sensitive. Passive sensitization with HDM evoked a weak early allergic response in PCLS from adult and newborn sheep, which notably was prolonged in airways from adult sheep. Only few mast cells were found in the lungs of non-sensitized sheep at both ages. Conclusion PCLS from sheep lungs represent a useful tool to study pharmacological airway responses for at least three days. Sheep seem well suited to study mechanisms of cholinergic airway contraction. The notable differences between newborn and adult sheep demonstrate the importance of age in such studies.
Collapse
Affiliation(s)
- Verena A. Lambermont
- Department of Pediatrics, Maastricht University Medical Center, Maastricht, the Netherlands
| | - Marco Schlepütz
- Institute of Pharmacology and Toxicology, University Hospital Aachen, Aachen, Germany
| | - Constanze Dassow
- Institute of Pharmacology and Toxicology, University Hospital Aachen, Aachen, Germany
| | - Peter König
- Institute of Anatomy, University of Lübeck, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Lübeck, Germany
| | - Luc J. Zimmermann
- Department of Pediatrics, Maastricht University Medical Center, Maastricht, the Netherlands
| | - Stefan Uhlig
- Institute of Pharmacology and Toxicology, University Hospital Aachen, Aachen, Germany
| | - Boris W. Kramer
- Department of Pediatrics, Maastricht University Medical Center, Maastricht, the Netherlands
| | - Christian Martin
- Institute of Pharmacology and Toxicology, University Hospital Aachen, Aachen, Germany
- * E-mail:
| |
Collapse
|
22
|
Calzetta L, Rogliani P, Cazzola M, Matera MG. Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond. Expert Opin Drug Discov 2014; 9:595-607. [PMID: 24749518 DOI: 10.1517/17460441.2014.909403] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Inhaled corticosteroid anti-inflammatory therapy is effective at controlling disease symptoms of asthma, but a subset of patients remains symptomatic despite optimal treatment, creating a clear unmet medical need. Moreover, none of the currently available drugs for asthma are really disease-modifying or curative. Although murine models of asthma, based on transgenic and knockout animals, may offer an integrated pathophysiological system for studying the characteristics of airway inflammation and hyperresponsiveness, these alterations are noteworthily different compared with those observed in asthmatic patients. Since a clear functional and inflammatory relationship between the nasal mucosa and bronchial tissue in patients suffering from asthma and allergic rhinitis has been recognized, using preclinical models based on human nasal cells sampling might support a prompt and effective anti-inflammatory drug discovery in asthma. AREAS COVERED The authors provide a review, which discusses the potential role of nasal cell sampling and its application in advanced drug discovery for asthma. The contents range from the similarities and differences between asthma and allergic rhinitis up to artificial airway models based on sophisticated human lung-on-a-chip devices. EXPERT OPINION Nasal cell sampling and processing have reached a great potential in asthma drug discovery. The authors believe that models of asthma, which are based on human nasal cells, can provide valuable indications of proof of pharmacological and potential therapeutic efficacy in both preclinical and early clinical settings.
Collapse
Affiliation(s)
- Luigino Calzetta
- IRCCS, San Raffaele Pisana Hospital, Department of Pulmonary Rehabilitation , Rome , Italy
| | | | | | | |
Collapse
|
23
|
Moy LY, Jia Y, Caniga M, Lieber G, Gil M, Fernandez X, Sirkowski E, Miller R, Alexander JP, Lee HH, Shin JD, Ellis JM, Chen H, Wilhelm A, Yu H, Vincent S, Chapman RW, Kelly N, Hickey E, Abraham WM, Northrup A, Miller T, Houshyar H, Crackower MA. Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction. Am J Respir Cell Mol Biol 2014; 49:1085-92. [PMID: 23889698 DOI: 10.1165/rcmb.2013-0200oc] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Spleen tyrosine kinase (SYK) is a key activator of signaling pathways downstream of multiple surface receptors implicated in asthma. SYK function has been extensively studied in mast cells downstream of the high-affinity IgE receptor, FcεR1. Preclinical studies have demonstrated a role for SYK in models of allergic inflammation, but a role in airway constriction has not been demonstrated. Here, we have used a potent and selective pharmacological inhibitor of SYK to determine the role of SYK in allergen-mediated inflammation and airway constriction in preclinical models. Attenuation of allergic airway responses was evaluated in a rat passive anaphylaxis model and rat and sheep inhaled allergen challenge models, as well as an ex vivo model of allergen-mediated airway constriction in rats and cynomolgus monkeys. Pharmacological inhibition of SYK dose-dependently blocked IgE-mediated tracheal plasma extravasation in rats. In a rat ovalbumin-sensitized airway challenge model, oral dosing with an SYK inhibitor led to a dose-dependent reduction in lung inflammatory cells. Ex vivo analysis of allergen-induced airway constriction in ovalbumin-sensitized brown Norway rats showed a complete attenuation with treatment of a SYK inhibitor, as well as a complete block of allergen-induced serotonin release. Similarly, allergen-mediated airway constriction was attenuated in ex vivo studies from nonhuman primate lungs. Intravenous administration of an SYK inhibitor attenuated both early- and late-phase allergen-induced increases in airway resistance in an Ascaris-sensitive sheep allergen challenge model. These data support a key role for SYK signaling in mediating allergic airway responses.
Collapse
|
24
|
Abstract
Live lung imaging has spanned the discovery of capillaries in the frog lung by Malpighi to the current use of single and multiphoton imaging of intravital and isolated perfused lung preparations incorporating fluorescent molecular probes and transgenic reporter mice. Along the way, much has been learned about the unique microcirculation of the lung, including immune cell migration and the mechanisms by which cells at the alveolar-capillary interface communicate with each other. In this review, we highlight live lung imaging techniques as applied to the role of mitochondria in lung immunity, mechanisms of signal transduction in lung compartments, studies on the composition of alveolar wall liquid, and neutrophil and platelet trafficking in the lung under homeostatic and inflammatory conditions. New applications of live lung imaging and the limitations of current techniques are discussed.
Collapse
Affiliation(s)
- Mark R. Looney
- Departments of Medicine and Laboratory Medicine, University of California, San Francisco, California 94143
| | - Jahar Bhattacharya
- Division of Pulmonary Allergy and Critical Care, Department of Medicine, and Department of Physiology & Cellular Biophysics, Columbia University College of Physicians & Surgeons, New York, New York 10032
| |
Collapse
|
25
|
Yousefi OS, Wilhelm T, Maschke-Neuß K, Kuhny M, Martin C, Molderings GJ, Kratz F, Hildenbrand B, Huber M. The 1,4-benzodiazepine Ro5-4864 (4-chlorodiazepam) suppresses multiple pro-inflammatory mast cell effector functions. Cell Commun Signal 2013; 11:13. [PMID: 23425659 PMCID: PMC3598916 DOI: 10.1186/1478-811x-11-13] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2012] [Accepted: 02/16/2013] [Indexed: 11/25/2022] Open
Abstract
Activation of mast cells (MCs) can be achieved by the high-affinity receptor for IgE (FcεRI) as well as by additional receptors such as the lipopolysaccharide (LPS) receptor and the receptor tyrosine kinase Kit (stem cell factor [SCF] receptor). Thus, pharmacological interventions which stabilize MCs in response to different receptors would be preferable in diseases with pathological systemic MC activation such as systemic mastocytosis. 1,4-Benzodiazepines (BDZs) have been reported to suppress MC effector functions. In the present study, our aim was to analyze molecularly the effects of BDZs on MC activation by comparison of the effects of the two BDZs Ro5-4864 and clonazepam, which markedly differ in their affinities for the archetypical BDZ recognition sites, i.e., the GABAA receptor and TSPO (previously termed peripheral-type BDZ receptor). Ro5-4864 is a selective agonist at TSPO, whereas clonazepam is a selective agonist at the GABAA receptor. Ro5-4864 suppressed pro-inflammatory MC effector functions in response to antigen (Ag) (degranulation/cytokine production) and LPS and SCF (cytokine production), whereas clonazepam was inactive. Signaling pathway analyses revealed inhibitory effects of Ro5-4864 on Ag-triggered production of reactive oxygen species, calcium mobilization and activation of different downstream kinases. The initial activation of Src family kinases was attenuated by Ro5-4864 offering a molecular explanation for the observed impacts on various downstream signaling elements. In conclusion, BDZs structurally related to Ro5-4864 might serve as multifunctional MC stabilizers without the sedative effect of GABAA receptor-interacting BDZs.
Collapse
Affiliation(s)
- Omid Sascha Yousefi
- Medical Faculty, Institute of Biochemistry and Molecular Immunology, RWTH Aachen University, Pauwelsstr, 30, 52074, Aachen, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Larsson-Callerfelt AK, Dahlén SE, Kühl AR, Lex D, Uhlig S, Martin C. Modulation of antigen-induced responses by serotonin and prostaglandin E2 via EP1 and EP4 receptors in the peripheral rat lung. Eur J Pharmacol 2013; 699:141-9. [DOI: 10.1016/j.ejphar.2012.11.039] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2011] [Revised: 11/15/2012] [Accepted: 11/23/2012] [Indexed: 02/02/2023]
|
27
|
Sewald K, Braun A. Assessment of immunotoxicity using precision-cut tissue slices. Xenobiotica 2013; 43:84-97. [PMID: 23199366 PMCID: PMC3518294 DOI: 10.3109/00498254.2012.731543] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2012] [Revised: 09/12/2012] [Accepted: 09/14/2012] [Indexed: 01/06/2023]
Abstract
1.When the immune system encounters incoming infectious agents, this generally leads to immunity. The evoked immune response is usually robust, but can be severely perturbed by potentially harmful environmental agents such as chemicals, pharmaceuticals and allergens. 2.Immunosuppression, hypersensitivity and autoimmunity may occur due to changed immune activity. Evaluation of the immunotoxic potency of agents as part of risk assessment is currently established in vivo with animal models and in vitro with cell lines or primary cells. 3.Although in vivo testing is usually the most relevant situation for many agents, more and more in vitro models are being developed for assessment of immunotoxicity. In this context, hypersensitivity and immunosuppression are considered to be a primary focus for developing in vitro methods. Three-dimensional organotypic tissue models are also part of current research in immunotoxicology. 4.In recent years, there has been a revival of interest in organotypic tissue models. In the context of immunotoxicity testing, precision-cut lung slices in particular have been intensively studied. Therefore, this review is very much focused on pulmonary immunotoxicology. Respiratory hypersensitivity and inflammation are further highlighted aspects of this review. Immunotoxicity assessment currently is of limited use in other tissue models, which are therefore described only briefly within this review.
Collapse
Affiliation(s)
- Katherina Sewald
- Department of Airway Immunology , Fraunhofer ITEM, Hannover, Germany.
| | | |
Collapse
|
28
|
Schlepütz M, Rieg AD, Seehase S, Spillner J, Perez-Bouza A, Braunschweig T, Schroeder T, Bernau M, Lambermont V, Schlumbohm C, Sewald K, Autschbach R, Braun A, Kramer BW, Uhlig S, Martin C. Neurally mediated airway constriction in human and other species: a comparative study using precision-cut lung slices (PCLS). PLoS One 2012; 7:e47344. [PMID: 23056631 PMCID: PMC3467211 DOI: 10.1371/journal.pone.0047344] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2012] [Accepted: 09/11/2012] [Indexed: 11/19/2022] Open
Abstract
The peripheral airway innervation of the lower respiratory tract of mammals is not completely functionally characterized. Recently, we have shown in rats that precision-cut lung slices (PCLS) respond to electric field stimulation (EFS) and provide a useful model to study neural airway responses in distal airways. Since airway responses are known to exhibit considerable species differences, here we examined the neural responses of PCLS prepared from mice, rats, guinea pigs, sheep, marmosets and humans. Peripheral neurons were activated either by EFS or by capsaicin. Bronchoconstriction in response to identical EFS conditions varied between species in magnitude. Frequency response curves did reveal further species-dependent differences of nerve activation in PCLS. Atropine antagonized the EFS-induced bronchoconstriction in human, guinea pig, sheep, rat and marmoset PCLS, showing cholinergic responses. Capsaicin (10 µM) caused bronchoconstriction in human (4 from 7) and guinea pig lungs only, indicating excitatory non-adrenergic non-cholinergic responses (eNANC). However, this effect was notably smaller in human responder (30 ± 7.1%) than in guinea pig (79 ± 5.1%) PCLS. The transient receptor potential (TRP) channel blockers SKF96365 and ruthenium red antagonized airway contractions after exposure to EFS or capsaicin in guinea pigs. In conclusion, the different species show distinct patterns of nerve-mediated bronchoconstriction. In the most common experimental animals, i.e. in mice and rats, these responses differ considerably from those in humans. On the other hand, guinea pig and marmoset monkey mimic human responses well and may thus serve as clinically relevant models to study neural airway responses.
Collapse
Affiliation(s)
- Marco Schlepütz
- Institute of Pharmacology and Toxicology, RWTH Aachen University, Aachen, Germany
| | - Annette D. Rieg
- Institute of Pharmacology and Toxicology, RWTH Aachen University, Aachen, Germany
| | - Sophie Seehase
- Department of Airway Immunology, Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany
- Encepharm GmbH, Göttingen, Germany
| | - Jan Spillner
- Department of Cardiothoracic and Vascular Surgery, RWTH Aachen University, Aachen, Germany
| | | | | | | | - Marc Bernau
- Institute of Pharmacology and Toxicology, RWTH Aachen University, Aachen, Germany
| | - Verena Lambermont
- School of Oncology and Developmental Biology, School of Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands
| | | | - Katherina Sewald
- Department of Airway Immunology, Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany
| | - Rüdiger Autschbach
- Department of Cardiothoracic and Vascular Surgery, RWTH Aachen University, Aachen, Germany
| | - Armin Braun
- Department of Airway Immunology, Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany
| | - Boris W. Kramer
- School of Oncology and Developmental Biology, School of Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands
| | - Stefan Uhlig
- Institute of Pharmacology and Toxicology, RWTH Aachen University, Aachen, Germany
| | - Christian Martin
- Institute of Pharmacology and Toxicology, RWTH Aachen University, Aachen, Germany
| |
Collapse
|
29
|
Wright D, Sharma P, Ryu MH, Rissé PA, Ngo M, Maarsingh H, Koziol-White C, Jha A, Halayko AJ, West AR. Models to study airway smooth muscle contraction in vivo, ex vivo and in vitro: implications in understanding asthma. Pulm Pharmacol Ther 2012; 26:24-36. [PMID: 22967819 DOI: 10.1016/j.pupt.2012.08.006] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/03/2012] [Revised: 08/14/2012] [Accepted: 08/17/2012] [Indexed: 11/16/2022]
Abstract
Asthma is a chronic obstructive airway disease characterised by airway hyperresponsiveness (AHR) and airway wall remodelling. The effector of airway narrowing is the contraction of airway smooth muscle (ASM), yet the question of whether an inherent or acquired dysfunction in ASM contractile function plays a significant role in the disease pathophysiology remains contentious. The difficulty in determining the role of ASM lies in limitations with the models used to assess contraction. In vivo models provide a fully integrated physiological response but ASM contraction cannot be directly measured. Ex vivo and in vitro models can provide more direct assessment of ASM contraction but the loss of factors that may modulate ASM responsiveness and AHR, including interaction between multiple cell types and disruption of the mechanical environment, precludes a complete understanding of the disease process. In this review we detail key advantages of common in vivo, ex vivo and in vitro models of ASM contraction, as well as emerging tissue engineered models of ASM and whole airways. We also highlight important findings from each model with respect to the pathophysiology of asthma.
Collapse
Affiliation(s)
- David Wright
- Medical Research Council and Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, United Kingdom
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Lavoie TL, Krishnan R, Siegel HR, Maston ED, Fredberg JJ, Solway J, Dowell ML. Dilatation of the constricted human airway by tidal expansion of lung parenchyma. Am J Respir Crit Care Med 2012; 186:225-32. [PMID: 22679010 DOI: 10.1164/rccm.201202-0368oc] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
RATIONALE In the normal lung, breathing and deep inspirations potently antagonize bronchoconstriction, but in the asthmatic lung this salutary effect is substantially attenuated or even reversed. To explain these findings, the prevailing hypothesis focuses on contracting airway smooth muscle and posits a nonlinear dynamic interaction between actomyosin binding and the tethering forces imposed by tidally expanding lung parenchyma. OBJECTIVE This hypothesis has never been tested directly in bronchial smooth muscle embedded within intraparenchymal airways. Our objective here is to fill that gap. METHODS We designed a novel system to image contracting intraparenchymal human airways situated within near-normal lung architecture and subjected to dynamic parenchymal expansion that simulates breathing. MEASUREMENTS AND MAIN RESULTS Reversal of bronchoconstriction depended on the degree to which breathing actually stretched the airway, which in turn depended negatively on severity of constriction and positively on the depth of breathing. Such behavior implies positive feedbacks that engender airway instability. OVERALL CONCLUSIONS These findings help to explain heterogeneity of airflow obstruction as well as why, in people with asthma, deep inspirations are less effective in reversing bronchoconstriction.
Collapse
Affiliation(s)
- Tera L Lavoie
- Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
| | | | | | | | | | | | | |
Collapse
|
31
|
Zhou J, Alvarez-Elizondo MB, Botvinick E, George SC. Local small airway epithelial injury induces global smooth muscle contraction and airway constriction. J Appl Physiol (1985) 2011; 112:627-37. [PMID: 22114176 DOI: 10.1152/japplphysiol.00739.2011] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Small airway epithelial cells form a continuous sheet lining the conducting airways, which serves many functions including a physical barrier to protect the underlying tissue. In asthma, injury to epithelial cells can occur during bronchoconstriction, which may exacerbate airway hyperreactivity. To investigate the role of epithelial cell rupture in airway constriction, laser ablation was used to precisely rupture individual airway epithelial cells of small airways (<300-μm diameter) in rat lung slices (∼250-μm thick). Laser ablation of single epithelial cells using a femtosecond laser reproducibly induced airway contraction to ∼70% of the original cross-sectional area within several seconds, and the contraction lasted for up to 40 s. The airway constriction could be mimicked by mechanical rupture of a single epithelial cell using a sharp glass micropipette but not with a blunt glass pipette. These results suggest that soluble mediators released from the wounded epithelial cell induce global airway contraction. To confirm this hypothesis, the lysate of primary human small airway epithelial cells stimulated a similar airway contraction. Laser ablation of single epithelial cells triggered a single instantaneous Ca(2+) wave in the epithelium, and multiple Ca(2+) waves in smooth muscle cells, which were delayed by several seconds. Removal of extracellular Ca(2+) or decreasing intracellular Ca(2+) both blocked laser-induced airway contraction. We conclude that local epithelial cell rupture induces rapid and global airway constriction through release of soluble mediators and subsequent Ca(2+)-dependent smooth muscle shortening.
Collapse
Affiliation(s)
- Jian Zhou
- Department of Biomedical Engineering, Universityof California, Irvine, CA 92697-2715, USA
| | | | | | | |
Collapse
|
32
|
Seehase S, Schlepütz M, Switalla S, Mätz-Rensing K, Kaup FJ, Zöller M, Schlumbohm C, Fuchs E, Lauenstein HD, Winkler C, Kuehl AR, Uhlig S, Braun A, Sewald K, Martin C. Bronchoconstriction in nonhuman primates: a species comparison. J Appl Physiol (1985) 2011; 111:791-8. [PMID: 21700889 DOI: 10.1152/japplphysiol.00162.2011] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Bronchoconstriction is a characteristic symptom of various chronic obstructive respiratory diseases such as chronic obstructive pulmonary disease and asthma. Precision-cut lung slices (PCLS) are a suitable ex vivo model to study physiological mechanisms of bronchoconstriction in different species. In the present study, we established an ex vivo model of bronchoconstriction in nonhuman primates (NHPs). PCLS prepared from common marmosets, cynomolgus macaques, rhesus macaques, and anubis baboons were stimulated with increasing concentrations of representative bronchoconstrictors: methacholine, histamine, serotonin, leukotriene D₄ (LTD₄), U46619, and endothelin-1. Alterations in the airway caliber were measured and compared with previously published data from rodents, guinea pigs, and humans. Methacholine induced maximal airway constriction, varying between 74 and 88% in all NHP species, whereas serotonin was ineffective. Histamine induced maximal bronchoconstriction of 77 to 90% in rhesus macaques, cynomolgus macaques, and baboons and a lesser constriction of 53% in marmosets. LTD₄ was ineffective in marmosets and rhesus macaques but induced a maximum constriction of 44 to 49% in cynomolgus macaques and baboons. U46619 and endothelin-1 caused airway constriction in all NHP species, with maximum constrictions of 65 to 91% and 70 to 81%, respectively. In conclusion, PCLS from NHPs represent a valuable ex vivo model for studying bronchoconstriction. All NHPs respond to mediators relevant to human airway disorders such as methacholine, histamine, U46619, and endothelin-1 and are insensitive to the rodent mast cell product serotonin. Only PCLS from cynomolgus macaques and baboons, however, responded also to leukotrienes, suggesting that among all compared species, these two NHPs resemble the human airway mechanisms best.
Collapse
Affiliation(s)
- S Seehase
- Department of Airway Immunology, Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Sanderson MJ. Exploring lung physiology in health and disease with lung slices. Pulm Pharmacol Ther 2011; 24:452-65. [PMID: 21600999 DOI: 10.1016/j.pupt.2011.05.001] [Citation(s) in RCA: 118] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/13/2010] [Revised: 05/03/2011] [Accepted: 05/05/2011] [Indexed: 10/24/2022]
Abstract
The development of therapeutic approaches to treat lung disease requires an understanding of both the normal and disease physiology of the lung. Although traditional experimental approaches only address either organ or cellular physiology, the use of lung slice preparations provides a unique approach to investigate integrated physiology that links the cellular and organ responses. Living lung slices are robust and can be prepared from a variety of species, including humans, and they retain many aspects of the cellular and structural organization of the lung. Functional portions of intrapulmonary airways, arterioles and veins are present within the alveoli parenchyma. The dynamics of macroscopic changes of contraction and relaxation associated with the airways and vessels are readily observed with conventional low-magnification microscopy. The microscopic changes associated with cellular events, that determine the macroscopic responses, can be observed with confocal or two-photon microscopy. To investigate disease processes, lung slices can either be prepared from animal models of disease or animals exposed to disease invoking conditions. Alternatively, the lung slices themselves can be experimentally manipulated. Because of the ability to observe changes in cell physiology and how these responses manifest themselves at the level of the organ, lung slices have become a standard tool for the investigation of lung disease.
Collapse
Affiliation(s)
- Michael J Sanderson
- Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01655, USA.
| |
Collapse
|
34
|
Schlepütz M, Uhlig S, Martin C. Electric field stimulation of precision-cut lung slices. J Appl Physiol (1985) 2010; 110:545-54. [PMID: 21109600 DOI: 10.1152/japplphysiol.00409.2010] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The precision-cut lung slice (PCLS) technique is widely used to examine airway responses in different species. We developed a method to study nerve-dependent bronchoconstriction by the application of electric field stimulation (EFS) to PCLS. PCLS prepared from Wistar rats were placed between two platinum electrodes to apply serial rectangular impulses (5-100 Hz), and bronchoconstriction was studied by videomicroscopy. The extent of airway contractions increased with higher frequencies. Stable repeated airway contractions were obtained at a frequency of 50 Hz, a width of 1 ms, and an output of 200 mA for 2.5 s each minute. Larger airways showed stronger responses. The EFS-triggered contractions were increased by the acetylcholine esterase inhibitor neostigmine (10 μM) and reversed by the muscarinic antagonist atropine (10 μM), whereas the thromboxane protanoid receptor antagonist SQ29548 (10 μM) had no effect. Magnesium ions (10 mM) antagonized airway contractions induced by EFS, but not by methacholine, indicating that nerve endings remain intact in PCLS. Our data further show that the electrically evoked airway contractions in PCLS are mediated by cholinergic nerves, independent of thromboxane and more prominent in larger airways. Taken together these findings show that nerve endings remain intact in PCLS, and they suggest that the present method is useful to study neurogenic responses in airways of different size.
Collapse
Affiliation(s)
- Marco Schlepütz
- Institute of Pharmacology and Toxicology, Univ. Hospital Aachen, Wendlingweg 2, 52074 Aachen.
| | | | | |
Collapse
|
35
|
Mosbah K, Stupar V, Berthezène Y, Beckmann N, Crémillieux Y. Spatially resolved assessment of serotonin-induced bronchoconstrictive responses in the rat lung using 3He ventilation MRI under spontaneous breathing conditions. Magn Reson Med 2010; 63:1669-74. [DOI: 10.1002/mrm.22391] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
36
|
Wohlsen A, Hirrle A, Tenor H, Marx D, Beume R. Effect of cyclic AMP-elevating agents on airway ciliary beat frequency in central and lateral airways in rat precision-cut lung slices. Eur J Pharmacol 2010; 635:177-83. [PMID: 20303939 DOI: 10.1016/j.ejphar.2010.03.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2009] [Revised: 02/12/2010] [Accepted: 03/03/2010] [Indexed: 01/27/2023]
Abstract
In patients with chronic obstructive pulmonary disease (COPD), mucociliary clearance of the respiratory tract is impaired due to enhanced mucus secretion and deterioration of normal ciliary activity. We investigated the effects of cyclic AMP-elevating agents with a different mode of action on ciliary beat frequency (CBF) in rat large central and small lateral airways by comparing the phosphodiesterase-4 (PDE4) inhibitors rolipram and roflumilast to the beta(2)-adrenoceptor agonist terbutaline and the adenylyl cyclase activator forskolin. Rat precision-cut lung slices were prepared and effects of cyclic AMP-elevating agents on CBF were assessed for up to 4h. In central airways a time- and concentration-dependent increase in CBF was seen for roflumilast (59+/-4%, 1microM, 60min), rolipram (55+/-4%, 1microM, 60min), terbutaline (64+/-8%, 10microM, 60min) and forskolin (55+/-8%, 100microM, 60min). Only roflumilast and rolipram increased CBF in lateral airways, with a similar time course and maximum efficacy (roflumilast 48+/-5%, rolipram 54+/-2%). Incubation of lateral airways with terbutaline (10microM, +11%) or forskolin (100microM, +1%) had negligible effects. As a major novel finding this study reveals that PDE4 inhibitors increased CBF in central as well as in lateral airways, while terbutaline and forskolin affected CBF in proximal airways only.
Collapse
Affiliation(s)
- Andrea Wohlsen
- Formerly Department of Preclinical Pharmacology, Nycomed GmbH, Konstanz, Germany
| | | | | | | | | |
Collapse
|
37
|
Dassow C, Wiechert L, Martin C, Schumann S, Müller-Newen G, Pack O, Guttmann J, Wall WA, Uhlig S. Biaxial distension of precision-cut lung slices. J Appl Physiol (1985) 2010; 108:713-21. [PMID: 20075265 DOI: 10.1152/japplphysiol.00229.2009] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The mechanical forces acting on lung parenchyma during (mechanical) ventilation and its (patho)physiological consequences are currently under intense scrutiny. Several in vivo and cell culture models have been developed to study the pulmonary responses to mechanical stretch. While providing extremely useful information, these models do also suffer from limitations in being either too complex for detailed mechanical or mechanistic studies, or in being devoid of the full complexity present in vivo (e.g., different cell types and interstitial matrix). Therefore in the present study it was our aim to develop a new model, based on the biaxial stretching of precision-cut lung slices (PCLS). Single PCLS were mounted on a thin and flexible carrier membrane of polydimethylsiloxane (PDMS) in a bioreactor, and the membrane was stretched by applying varying pressures under static conditions. Distension of the membrane-PCLS construct was modeled via finite element simulation. According to this analysis, lung tissue was stretched by up to 38% in the latitudinal and by up to 44% in the longitudinal direction, resulting in alveolar distension similar to what has been described in intact lungs. Stretch for 5 min led to increased cellular calcium levels. Lung slices were stretched dynamically with a frequency of 15/min for 4 h without causing cell injury {3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) test; live/dead straining}. These findings suggest that stretching of PCLS on PDMS-membranes may represent a useful model to investigate lung stretch in intact lung tissue in vitro for several hours.
Collapse
Affiliation(s)
- C Dassow
- Institute of Pharmacology and Toxicology, Medical Faculty, RWTH Aachen University, Wendlingweg 2, 52074 Aachen, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Arts JHE, Jacobs EJ, Kuper CF. Pre-exposure to sulfur dioxide attenuates most allergic reactions upon trimellitic anhydride challenge in sensitized Brown Norway rats. Inhal Toxicol 2010; 22:179-91. [DOI: 10.3109/08958370902828468] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
39
|
Cyphert JM, Kovarova M, Allen IC, Hartney JM, Murphy DL, Wess J, Koller BH. Cooperation between mast cells and neurons is essential for antigen-mediated bronchoconstriction. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2009; 182:7430-9. [PMID: 19494266 PMCID: PMC3901060 DOI: 10.4049/jimmunol.0900039] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Mast cells are important sentinels guarding the interface between the environment and the body: a breach in the integrity of this interface can lead to the release of a plethora of mediators that engage the foreign agent, recruit leukocytes, and initiate adaptive physiological changes in the organism. While these capabilities make mast cells critical players in immune defense, it also makes them important contributors to the pathogenesis of diseases such as asthma. Mast cell mediators induce dramatic changes in smooth muscle physiology, and the expression of receptors for these factors by smooth muscle suggests that they act directly to initiate constriction. Contrary to this view, we show herein that mast cell-mediated bronchoconstriction is observed only in animals with intact innervation of the lung and that serotonin release alone is required for this action. While ablation of sensory neurons does not limit bronchoconstriction, constriction after Ag challenge is absent in mice in which the cholinergic pathways are compromised. Linking mast cell function to the cholinergic system likely provides an important means of modulating the function of these resident immune cells to physiology of the lung, but may also provide a safeguard against life-threatening anaphylaxis during mast cell degranulation.
Collapse
Affiliation(s)
- Jaime M Cyphert
- Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
| | | | | | | | | | | | | |
Collapse
|
40
|
Cooper PR, McParland BE, Mitchell HW, Noble PB, Politi AZ, Ressmeyer AR, West AR. Airway mechanics and methods used to visualize smooth muscle dynamics in vitro. Pulm Pharmacol Ther 2008; 22:398-406. [PMID: 19041411 DOI: 10.1016/j.pupt.2008.09.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/02/2008] [Accepted: 09/01/2008] [Indexed: 11/24/2022]
Abstract
Contraction of airway smooth muscle (ASM) is regulated by the physiological, structural and mechanical environment in the lung. We review two in vitro techniques, lung slices and airway segment preparations, that enable in situ ASM contraction and airway narrowing to be visualized. Lung slices and airway segment approaches bridge a gap between cell culture and isolated ASM, and whole animal studies. Imaging techniques enable key upstream events involved in airway narrowing, such as ASM cell signalling and structural and mechanical events impinging on ASM, to be investigated.
Collapse
Affiliation(s)
- P R Cooper
- Department of Medicine and the Airway Biology Initiative, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
| | | | | | | | | | | | | |
Collapse
|
41
|
Henjakovic M, Martin C, Hoymann HG, Sewald K, Ressmeyer AR, Dassow C, Pohlmann G, Krug N, Uhlig S, Braun A. Ex Vivo Lung Function Measurements in Precision-Cut Lung Slices (PCLS) from Chemical Allergen–Sensitized Mice Represent a Suitable Alternative to In Vivo Studies. Toxicol Sci 2008; 106:444-53. [DOI: 10.1093/toxsci/kfn178] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
|
42
|
Henjakovic M, Sewald K, Switalla S, Kaiser D, Müller M, Veres TZ, Martin C, Uhlig S, Krug N, Braun A. Ex vivo testing of immune responses in precision-cut lung slices. Toxicol Appl Pharmacol 2008; 231:68-76. [PMID: 18504053 DOI: 10.1016/j.taap.2008.04.003] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2008] [Revised: 04/02/2008] [Accepted: 04/02/2008] [Indexed: 10/24/2022]
Abstract
The aim of this study was the establishment of precision-cut lung slices (PCLS) as a suitable ex vivo alternative approach to animal experiments for investigation of immunomodulatory effects. For this purpose we characterized the changes of cytokine production and the expression of cell surface markers after incubation of PCLS with immunoactive substances lipopolysaccharide (LPS), macrophage-activating lipopeptide-2 (MALP-2), interferon gamma (IFNgamma), and dexamethasone. Viability of PCLS from wild-type and CD11c-enhanced yellow fluorescent protein (CD11-EYFP)-transgenic mice was controlled by measurement of lactate dehydrogenase (LDH) enzyme activity and live/dead fluorescence staining using confocal microscopy. Cytokines and chemokines were detected with Luminex technology and ELISA. Antigen presenting cell (APC) markers were investigated in living mouse PCLS in situ using confocal microscopy. LPS triggered profound pro-inflammatory effects in PCLS. Dexamethasone prevented LPS-induced production of cytokines/chemokines such as interleukin (IL)-5, IL-1alpha, TNFalpha, IL-12(p40), and RANTES in PCLS. Surface expression of MHC class II, CD40, and CD11c, but not CD86 was present in APCs of naive PCLS. Incubation with LPS enhanced specifically the expression of MHC class II on diverse cells. MALP-2 only failed to alter cytokine or chemokine levels, but was highly effective in combination with IFNgamma resulting in increased levels of TNFalpha, IL-12(p40), RANTES, and IL-1alpha. PCLS showed characteristic responses to typical pro-inflammatory stimuli and may thus provide a suitable ex vivo technique to predict the immunomodulatory potency of inhaled substances.
Collapse
Affiliation(s)
- M Henjakovic
- Fraunhofer Institute of Toxicology and Experimental Medicine, Department of Immunology, Allergology and Immunotoxicology, Nikolai-Fuchs-Str. 1, 30625 Hannover, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Erpenbeck VJ, Ziegert M, Cavalet-Blanco D, Martin C, Baelder R, Glaab T, Braun A, Steinhilber W, Luettig B, Uhlig S, Hoymann HG, Krug N, Hohlfeld JM. Surfactant protein D inhibits early airway response in Aspergillus fumigatus-sensitized mice. Clin Exp Allergy 2007; 36:930-40. [PMID: 16839409 DOI: 10.1111/j.1365-2222.2006.02524.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
BACKGROUND The surfactant protein SP-D has been reported to reduce bronchial hyper-responsiveness, blood eosinophilia, and T-helper type 2 cytokines in models of allergic asthma. However, little is known about the functional effect of SP-D on the early airway response upon allergen inhalation, which is an important feature of this disease. OBJECTIVE We investigated whether SP-D is able to reduce the immediate allergen-induced mediator release and the early bronchial obstruction in addition to its effects on airway inflammation and bronchial hyperresponsiveness in an Aspergillus fumigatus mouse asthma model. METHODS A. fumigatus-sensitized mice were treated with a recombinant fragment of human SP-D or placebo. Lung functions were measured in orotracheally intubated, spontaneously breathing animals using body plethysmography. In addition, passively sensitized precision-cut lung slices (PCLS) were used to determine the effect of SP-D on allergen-induced histamine release. RESULTS SP-D inhibited the allergen-induced early airway response and reduced airway hyperresponsiveness compared with placebo. Eosinophilia in bronchoalveolar lavage and lung tissue was reduced after SP-D treatment, possibly by reducing eotaxin levels in the lung. Furthermore, SP-D treatment reduced the allergen-induced histamine release from PCLS. CONCLUSION These data suggest that SP-D not only reduces allergen-induced eosinophilic inflammation and airway hyperresponsiveness but also provides protection against early airway obstruction by inhibition of early mediator release.
Collapse
Affiliation(s)
- V J Erpenbeck
- Fraunhofer Institute of Toxicology and Experimental Medicine, Hannover, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Moss OR, Oldham MJ. Dosimetry counts: molecular hypersensitivity may not drive pulmonary hyperresponsiveness. ACTA ACUST UNITED AC 2007; 19:555-64. [PMID: 17196083 DOI: 10.1089/jam.2006.19.555] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Airway hyperresponsiveness is one measure of allergic asthma. One such test, the methacholine challenge, uses an inhaled aerosol to induce changes in resistance to breathing. The test is also used to test hyperresponsiveness in rodent models of asthma. For two varieties of mice, the B6C3F1 and the Balb/c, exposure to aerosolized methacholine demonstrates that the Balb/c is 12x more responsive based on the concentration of methacholine in the solution used to produce the inhaled aerosol (the normally accepted dose-metric). Here we show that the 12x difference in exposure disappears when measurements of airway dimensions of generations 1-6 are used first to calculate deposited mass of methacholine; and second to account for the physiology of airway constriction and pressure drop. These observations in mice provide one explanation of how some hyperresponsive subjects can have no underlying molecular sensitivity; and how constriction in the upper airways can have greater impact on breathing than constriction of airway generations 6-16.
Collapse
Affiliation(s)
- O R Moss
- CIIT Centers for Health Research, Research Triangle Park, North Carolina 27709, USA.
| | | |
Collapse
|
45
|
Small airway relaxation--a forgotten medical need. Pulm Pharmacol Ther 2006; 21:1-3. [PMID: 17169595 DOI: 10.1016/j.pupt.2006.10.017] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/07/2006] [Accepted: 10/30/2006] [Indexed: 11/22/2022]
Abstract
The current exclusive focus on airway inflammation and remodelling in asthma and chronic obstructive pulmonary disease has dwarfed the interest in simple relaxation of the bronchi. This commentary highlights the particular importance of reducing smooth muscle constriction of human small airways in these obstructive diseases. Furthermore, the need of novel drugs in this area is underscored by in vitro and in vivo data demonstrating limited small airway relaxant efficacy of currently available bronchodilators.
Collapse
|
46
|
Bai Y, Zhang M, Sanderson MJ. Contractility and Ca2+ signaling of smooth muscle cells in different generations of mouse airways. Am J Respir Cell Mol Biol 2006; 36:122-30. [PMID: 16931808 PMCID: PMC1899303 DOI: 10.1165/rcmb.2006-0036oc] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
The control and mechanisms of airway smooth muscle cell (SMC) contraction were investigated with a sequential series of lung slices from different generations of the same airway from the cardiac lobe of the mouse lung. Airway contraction was measured by monitoring the changes in airway lumen area with phase-contrast microscopy. Changes in intracellular calcium concentration of the SMCs were studied with a custom-built confocal or two-photon microscope. The distribution of the airway SMCs and the muscarinic M(3) or 5-HT(2A) receptors was determined with immunofluorescence. Methacholine and 5-HT induced a concentration-dependent airway contraction and Ca(2+) oscillations within the SMCs of each airway generation. The airway contraction in response to the same agonist concentration was greater in the middle generation compared with the distal or proximal generations of the same airway. Similarly, the Ca(2+) oscillations varied in different generations of the same airway, with a slower frequency in the SMCs of the distal zone as compared with the middle or proximal zones of airways. By contrast, high KCl induced minimal contraction and very slow Ca(2+) oscillations throughout the whole intrapulmonary airway. The slower agonist-induced Ca(2+) oscillations in the distal zone correlated with a reduced expression of agonist receptors. The layer of SMCs increased in thickness in the middle and proximal zones. These results indicate that the contractility of airway SMCs varies at different positions along the same airway and that this response partially results from different Ca(2+) signaling and the total amount of the SMCs.
Collapse
Affiliation(s)
- Yan Bai
- Department of Physiology, University of Massachusetts Medical School, Worcester, MA 01655, USA
| | | | | |
Collapse
|
47
|
Bayat S, Porra L, Suhonen H, Nemoz C, Suortti P, Sovijärvi ARA. Differences in the time course of proximal and distal airway response to inhaled histamine studied by synchrotron radiation CT. J Appl Physiol (1985) 2006; 100:1964-73. [PMID: 16469938 DOI: 10.1152/japplphysiol.00594.2005] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
We studied the kinetics of proximal and distal bronchial response to histamine aerosol in healthy anesthetized and mechanically ventilated rabbits up to 60 min after histamine administration using a novel xenon-enhanced synchrotron radiation computed tomography imaging technique. Individual proximal airway constriction was assessed by measuring the luminal cross-sectional area. Distal airway obstruction was estimated by measuring the ventilated alveolar area after inhaled xenon administration. Respiratory system conductance was assessed continuously. Proximal airway cross-sectional area decreased by 57% of the baseline value by 20 min and recovered gradually but incompletely within 60 min. The ventilated alveolar area decreased immediately after histamine inhalation by 55% of baseline value and recovered rapidly thereafter. The results indicate that the airway reaction to inhaled histamine and the subsequent recovery are significantly slower in proximal than in distal bronchi in healthy rabbit. The findings suggest that physiological reaction mechanisms to inhaled histamine in the airway walls of large and small bronchi are not similar.
Collapse
Affiliation(s)
- Sam Bayat
- European Synchrotron Radiation Facility, Medical Beamline-ID17, Grenoble, France.
| | | | | | | | | | | |
Collapse
|
48
|
Perez JF, Sanderson MJ. The frequency of calcium oscillations induced by 5-HT, ACH, and KCl determine the contraction of smooth muscle cells of intrapulmonary bronchioles. ACTA ACUST UNITED AC 2005; 125:535-53. [PMID: 15928401 PMCID: PMC2234076 DOI: 10.1085/jgp.200409216] [Citation(s) in RCA: 147] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
Increased resistance of airways or blood vessels within the lung is associated with asthma or pulmonary hypertension and results from contraction of smooth muscle cells (SMCs). To study the mechanisms regulating these contractions, we developed a mouse lung slice preparation containing bronchioles and arterioles and used phase-contrast and confocal microscopy to correlate the contractile responses with changes in [Ca2+]i of the SMCs. The airways are the focus of this study. The agonists, 5-hydroxytrypamine (5-HT) and acetylcholine (ACH) induced a concentration-dependent contraction of the airways. High concentrations of KCl induced twitching of the airway SMCs but had little effect on airway size. 5-HT and ACH induced asynchronous oscillations in [Ca2+]i that propagated as Ca2+ waves within the airway SMCs. The frequency of the Ca2+ oscillations was dependent on the agonist concentration and correlated with the extent of sustained airway contraction. In the absence of extracellular Ca2+ or in the presence of Ni2+, the frequency of the Ca2+ oscillations declined and the airway relaxed. By contrast, KCl induced low frequency Ca2+ oscillations that were associated with SMC twitching. Each KCl-induced Ca2+ oscillation consisted of a large Ca2+ wave that was preceded by multiple localized Ca2+ transients. KCl-induced responses were resistant to neurotransmitter blockers but were abolished by Ni2+ or nifedipine and the absence of extracellular Ca2+. Caffeine abolished the contractile effects of 5-HT, ACH, and KCl. These results indicate that (a) 5-HT and ACH induce airway SMC contraction by initiating Ca2+ oscillations, (b) KCl induces Ca2+ transients and twitching by overloading and releasing Ca2+ from intracellular stores, (c) a sustained, Ni2+-sensitive, influx of Ca2+ mediates the refilling of stores to maintain Ca2+ oscillations and, in turn, SMC contraction, and (d) the magnitude of sustained airway SMC contraction is regulated by the frequency of Ca2+ oscillations.
Collapse
Affiliation(s)
- Jose F Perez
- Department of Physiology, University of Massachusetts Medical School, Worcester, MA 01655, USA
| | | |
Collapse
|
49
|
Valstar DL, Schijf MA, Nijkamp FP, Storm G, Arts JHE, Kuper CF, Bloksma N, Henricks PAJ. Alveolar macrophages have a dual role in a rat model for trimellitic anhydride-induced occupational asthma. Toxicol Appl Pharmacol 2005; 211:20-9. [PMID: 15992840 DOI: 10.1016/j.taap.2005.05.012] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2005] [Revised: 05/13/2005] [Accepted: 05/13/2005] [Indexed: 10/25/2022]
Abstract
Occupational exposure to low molecular weight chemicals, like trimellitic anhydride (TMA), can result in occupational asthma. Alveolar macrophages (AMs) are among the first cells to encounter inhaled compounds. These cells can produce many different mediators that have a putative role in asthma. In this study, we examined the role of AMs in lung function and airway inflammation of rats exposed to TMA. Female Brown Norway rats were sensitized by dermal application of TMA or received vehicle alone on days 0 and 7. One day before challenge, rats received intratracheally either empty or clodronate-containing liposomes to deplete the lungs of AMs. On day 21, all rats were challenged by inhalation of TMA in air. Lung function parameters were measured before, during, within 1 h after, and 24 h after challenge. IgE levels and parameters of inflammation and tissue damage were assessed 24 h after challenge. Sensitization with TMA led to decreased lung function parameters during and within 1 h after challenge as compared to non-sensitized rats. AM depletion alleviated the TMA-induced drop in lung function parameters and induced a faster recovery compared to sham-depleted TMA-sensitized rats. It also decreased the levels of serum IgE 24 h after challenge, but did not affect the sensitization-dependent increase in lung lavage fluid IL-6 and tissue TNF-alpha levels. In contrast, AM depletion augmented the TMA-induced tissue damage and inflammation 24 h after challenge. AMs seem to have a dual role in this model for TMA-induced occupational asthma since they potentiate the immediate TMA-induced decrease in lung function but tended to dampen the TMA-induced inflammatory reaction 24 h later.
Collapse
Affiliation(s)
- Dingena L Valstar
- Department of Pharmacology and Pathophysiology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Sorbonnelaan 16, 3584 CA, Utrecht, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Pfaff M, Powaga N, Akinci S, Schütz W, Banno Y, Wiegand S, Kummer W, Wess J, Haberberger RV. Activation of the SPHK/S1P signalling pathway is coupled to muscarinic receptor-dependent regulation of peripheral airways. Respir Res 2005; 6:48. [PMID: 15927078 PMCID: PMC1156956 DOI: 10.1186/1465-9921-6-48] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2004] [Accepted: 05/31/2005] [Indexed: 12/16/2022] Open
Abstract
Background In peripheral airways, acetylcholine induces contraction via activation of muscarinic M2-and M3-receptor subtypes (M2R and M3R). Cholinergic hypersensitivity is associated with chronic obstructive pulmonary disease and asthma, and therefore the identification of muscarinic signaling pathways are of great therapeutic interest. A pathway that has been shown to be activated via MR and to increase [Ca2+]i includes the activation of sphingosine kinases (SPHK) and the generation of the bioactive sphingolipid sphingosine 1-phosphate (S1P). Whether the SPHK/S1P signaling pathway is integrated in the muscarinic control of peripheral airways is not known. Methods To address this issue, we studied precision cut lung slices derived from FVB and M2R-KO and M3R-KO mice. Results In peripheral airways of FVB, wild-type, and MR-deficient mice, SPHK1 was mainly localized to smooth muscle. Muscarine induced a constriction in all investigated mouse strains which was reduced by inhibition of SPHK using D, L-threo-dihydrosphingosine (DHS) and N, N-dimethyl-sphingosine (DMS) but not by N-acetylsphingosine (N-AcS), a structurally related agent that does not affect SPHK function. The initial phase of constriction was nearly absent in peripheral airways of M3R-KO mice when SPHK was inhibited by DHS and DMS but was unaffected in M2R-KO mice. Quantitative RT-PCR revealed that the disruption of the M2R and M3R genes had no significant effect on the expression levels of the SPHK1-isoform in peripheral airways. Conclusion These results demonstrate that the SPHK/S1P signaling pathway contributes to cholinergic constriction of murine peripheral airways. In addition, our data strongly suggest that SPHK is activated via the M2R. Given the important role of muscarinic mechanisms in pulmonary disease, these findings should be of considerable therapeutic relevance.
Collapse
Affiliation(s)
- Melanie Pfaff
- Institute for Anatomy and Cell Biology Justus-Liebig-University Giessen, Germany
| | - Norbert Powaga
- Institute for Anatomy and Cell Biology Justus-Liebig-University Giessen, Germany
| | - Sibel Akinci
- Institute for Anatomy and Cell Biology Justus-Liebig-University Giessen, Germany
| | - Werner Schütz
- Institute for Anatomy and Cell Biology Justus-Liebig-University Giessen, Germany
| | - Yoshiko Banno
- Department of Cell Signaling, Graduate School of Medicine, Gifu University, Gifu, Japan
| | - Silke Wiegand
- Institute for Anatomy and Cell Biology Justus-Liebig-University Giessen, Germany
| | - Wolfgang Kummer
- Institute for Anatomy and Cell Biology Justus-Liebig-University Giessen, Germany
| | - Jürgen Wess
- Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive Kidney Diseases, Bethesda, Maryland 20892, USA
| | | |
Collapse
|